Hong Kong's regulatory reforms mostly welcomed by pharma
This article was originally published in Scrip
The pharmaceutical industry in Hong Kong has generally welcomed a set of far-reaching recommendations to come out of an official review of pharmaceutical regulation in the territory, although it has lingering concerns about their full implementation.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.